Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;9(3):1844.
doi: 10.29011/2574-7754.101844. Epub 2024 Jun 13.

Deferoxamine Intradermal Delivery Patch for Treatment of a Radiation Therapy Associated Breast Wound

David Perrault  1   2 , Kellen Chen  3 , Rahim Nazerali  2 , Derrick Wan  1   2
Affiliations

Deferoxamine Intradermal Delivery Patch for Treatment of a Radiation Therapy Associated Breast Wound

David Perrault et al. Ann Case Rep. 2024.

Abstract

Purpose: Radiation therapy is used in over 60% of cancer patients and can lead to radiation dermatitis, radiation induced fibrosis, hyperpigmentation, telangiectasias, fat necrosis, and poor wound healing. Deferoxamine (DFO) is an iron-chelating agent that has been used systemically to treat iron overload conditions and more recently been studied to treat radiation fibrosis. Through iron chelation, DFO stabilizes hypoxia inducible factor-1α, driving downstream upregulation of angiogenic factors, and reduces formation of reactive oxygen species, thereby offering a potential therapy for radiation associated chronic wounds. The purpose of this work was to describe treatment of a refractory wound following radiation treatment that had failed conventional therapy.

Methods: The patient is a 71-year-old female with inflammatory breast cancer that developed a radiation related wound after mastectomy, chemotherapy, and radiation therapy. The wound did not show any signs of improvement with five months of wound care and risk factor modification. The patient was offered treatment with a topical Deferoxamine Intradermal Delivery Patch through the FDA single patient investigative new drug pathway.

Results: After two weeks of treatment, the wound healed. Additionally, serum was collected at cessation of therapy and 5 weeks after, with both samples showing no significant systemically detectible level of the drug to be present. Subjectively the patient reported improvement in appearance and quality of the skin.

Conclusion: Topical deferoxamine is a promising therapy for radiation wounds. Although this report is limited to a single patient experience, we believe this work is important in describing the first in-human use of topical deferoxamine to heal a radiation therapy associated wound.

Keywords: Chronic Wounds; Deferoxamine; Iron Chelation; Radiation; Radiation Wounds; Wound Healing.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors hold no conflict of interest.

Figures

Figure 1:
Figure 1:
Radiation breast wound before and after treatment with topical deferoxamine.
Figure 2:
Figure 2:
Deferoxamine Intradermal Delivery Patch applied to radiation breast wound.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. FitzGerald TJ, Bishop-Jodoin M, Laurie F, Lukez A, O’Loughlin L, et al. (2019) Treatment Toxicity: Radiation. Hematol Oncol Clin North Am 33(6):1027–1039. - PubMed
    1. Bryant AK, Banegas MP, Martinez ME, Mell LK, Murphy JD (2017) Trends in Radiation Therapy among Cancer Survivors in the United States, 2000–2030. Cancer Epidemiol Biomarkers Prev. 26(6):963–970. - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, et al. (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. - PMC - PubMed
    1. Tevlin R, Longaker MT, Wan DC (2021) Deferoxamine to Minimize Fibrosis During Radiation Therapy. Adv Wound Care (New Rochelle). 11(10):548–559. - PMC - PubMed
    1. Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, et al. (2017) Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol.18(2):259–268. - PubMed

LinkOut - more resources